Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 2
2001 10
2002 25
2003 23
2004 35
2005 31
2006 40
2007 44
2008 50
2009 83
2010 74
2011 110
2012 112
2013 105
2014 116
2015 95
2016 71
2017 60
2018 50
2019 35
2020 43
2021 45
2022 28
2023 10
Text availability
Article attribute
Article type
Publication date

Search Results

1,136 results
Results by year
Filters applied: . Clear all
Page 1
[Olmesartan-associated Enteropathy].
Zou L, Wang Q, Li Y, Yang AM. Zou L, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021 Dec 30;43(6):986-990. doi: 10.3881/j.issn.1000-503X.13268. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021. PMID: 34980342 Review. Chinese.
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent years have described a severe gastrointestinal adverse event with chronic diarrhea,intestinal malabsorption,and weight loss after the admin …
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent …
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. ...The safety and tolerability profiles of sacubitril/valsarta

…
Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitr …
Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Huo Y, et al. J Clin Hypertens (Greenwich). 2019 Jan;21(1):67-76. doi: 10.1111/jch.13437. Epub 2018 Dec 11. J Clin Hypertens (Greenwich). 2019. PMID: 30536595 Free PMC article. Clinical Trial.
The primary endpoint was reduction in mean sitting systolic blood pressure (msSBP) from baseline with sacubitril/valsartan 200 mg vs olmesartan 20 mg at Week 8. Secondary endpoints included msSBP reduction with sacubitril/valsartan 400 mg, and reductions in clinic and ambu …
The primary endpoint was reduction in mean sitting systolic blood pressure (msSBP) from baseline with sacubitril/valsartan 200 mg vs olme …
Olmesartan.
Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Al-Jallal AAM. Al-Majed AA, et al. Profiles Drug Subst Excip Relat Methodol. 2017;42:241-286. doi: 10.1016/bs.podrm.2017.02.005. Epub 2017 Mar 31. Profiles Drug Subst Excip Relat Methodol. 2017. PMID: 28431778
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. ...Comprehensive pharmacology is also presented (pharmacologi …
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood …
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Williams B, et al. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. Epub 2017 Jan 16. Hypertension. 2017. PMID: 28093466 Clinical Trial.
Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, was conducted to …
Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, …
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, Hrabak-Paar M, Heye T, Aichner S, Khder Y, Yates D, Albrecht D, Langenickel T, Freyhardt P, Janka R, Bremerich J. Schmieder RE, et al. Eur Heart J. 2017 Nov 21;38(44):3308-3317. doi: 10.1093/eurheartj/ehx525. Eur Heart J. 2017. PMID: 29029087 Clinical Trial.
Left ventricular mass index decreased to a greater extent in the sacubitril/valsartan group compared to the olmesartan group from baseline to 12 weeks (-6.36 vs. -2.32 g/m2; P = 0.039) and from baseline to 52 weeks (-6.83 vs. -3.55 g/m2; P = 0.029). ...There were no signif …
Left ventricular mass index decreased to a greater extent in the sacubitril/valsartan group compared to the olmesartan group from bas …
Olmesartan-induced enteropathy.
Onteddu NK, Pulivarthi VSKK, Ginnavaram M, Kedika R. Onteddu NK, et al. BMJ Case Rep. 2018 Oct 2;2018:bcr2018224411. doi: 10.1136/bcr-2018-224411. BMJ Case Rep. 2018. PMID: 30279248 Free PMC article.
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. ...This report serves as an addition to existing literature and to increase the awareness of olmesa …
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weigh …
Olmesartan-Induced Enteropathy.
Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E. Adike A, et al. Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):230-232. doi: 10.14797/mdcj-12-4-230. Methodist Debakey Cardiovasc J. 2016. PMID: 28289500 Free PMC article.
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea …
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are …
Olmesartan-associated enteropathy: Belgian survey.
Allaoui A, Marcoux D, Vokaer B, Couturier B. Allaoui A, et al. Therapie. 2021 Jan-Feb;76(1):58-60. doi: 10.1016/j.therap.2020.02.023. Epub 2020 Mar 29. Therapie. 2021. PMID: 32284216 No abstract available.
Olmesartan-induced enteropathy: More than one entity?
Famularo G, Aglitti A, Magrini L. Famularo G, et al. Eur J Intern Med. 2022 Nov;105:113. doi: 10.1016/j.ejim.2022.06.025. Epub 2022 Jul 5. Eur J Intern Med. 2022. PMID: 35798591 No abstract available.
1,136 results